AVTI Avitar Inc (CE)

Avitar Inc. (�AVTI�) (OTCBB:AVTI), manufacturers of nationally branded oral fluid testing diagnostic devices and customized polyurethane applications used in wound dressings, announced today that the Company�s ORALscreen rapid test for drugs-of-abuse are being piloted and moving towards nationwide deployment at two of the largest construction firms in the United States. Peter Phildius, Avitar�s Chairman and CEO said, �The construction industry represents a significant business opportunity for Avitar, a revenue potential of $1M over the next year. Industry leaders are now moving to incorporate Avitar�s on-site oral fluid technology for random drug testing, as well as pre-employment, post-accident, and reasonable suspicion applications, previously done with traditional urine testing. We have also expanded our client list of small to medium-sized contractors and continue to develop a solid understanding of the needs of the construction sector, where we believe our integrated drug-free workplace solutions offer true value.� Avitar has been focusing on meeting construction safety requirements for the past two years, and also continues to make progress educating and gaining approvals from multiple union locals, including Carpenters, Ironworkers, Steelworkers, IBEW, as well as the Longshoremen's Union where Avitar products are being used at several seaports. Additionally, State Governments are recognizing the value of oral fluid to the construction sector. For example, the States of Hawaii and Georgia recently passed legislation providing Worker's Compensation premium discounts for the use of on-site oral fluid devices. In Hawaii, the Carpenters Union spearheaded the change. About Avitar, Inc. Avitar Inc. develops, manufactures and markets innovative proprietary products. Markets include fluid diagnostics, disease and clinical testing, and customized applications for wound dressings. Principal products include ORALscreen�, (the first non-invasive, rapid, onsite oral fluid test for drugs-of-abuse), and Hydrasorb�, (an absorbent topical dressing for moderate to heavy exudating wounds). Avitar is also developing diagnostic strategies for disease and clinical testing in the estimated $25 billion in-vitro diagnostics market. Conditions targeted include influenza, diabetes, and pregnancy. For more information, see Avitar's website at http://www.avitarinc.com. Avitar Inc. is a fully reporting company whose stock trades on the OTCBB under the symbol �AVTI.OB�. Forward-Looking Statements This release contains forward-looking statements that are subject to risks and uncertainties including the development and marketing of new applications and other risks that are detailed from time to time in the Company�s filings with the Securities and Exchange Commission. In view of such risks and uncertainties, the Company�s actual results could differ materially from those anticipated in such forward-looking statements.